Sensydia, a US-based medical technology company developing non-invasive cardiac assessment systems, has secured more than $6 million in an oversubscribed initial closing of its latest financing. The funding was led by Colle Capital Partners, with participation from Orlando Health Ventures.
Founded in 2015, Sensydia was co-founded by Dr. Aman Mahajan and William J. Kaiser. The company is led by CEO Anthony Arnold and focuses on developing technologies to assess cardiac function without invasive diagnostic procedures.
Sensydia is developing the Cardiac Performance System (CPS), a non-invasive medical device designed to measure hemodynamic parameters, including pulmonary artery pressure, using acoustic and electrical signals analyzed by artificial intelligence algorithms.
The system is intended to help clinicians assess patients with heart failure and pulmonary hypertension in hospitals, clinics and physicians’ offices. Its approach aims to make cardiac pressure measurements available without requiring invasive right-heart catheterization.
Sensydia plans to use the new capital to advance CPS through its ongoing ACOUSTIC-1 clinical study, support its pursuit of US Food and Drug Administration (FDA) authorization and prepare for commercial launch. The study evaluates the system’s measurement accuracy against invasive right-heart catheterization.
The company previously received FDA Breakthrough Device designation for CPS in January 2022. It also obtained FDA 510(k) clearance in 2018 for an earlier generation of its non-invasive ejection fraction measurement technology. The current CPS system remains investigational and has not yet received FDA authorization.
In May 2023, Sensydia announced approximately $8 million in financing to support the development and commercialization preparation of its cardiac assessment platform.
